Current preclinical evidence indicates that RES is effective at reducing alanine aminotransferase (ALT) and hepatic steatosis in patients with non-alcoholic fatty liver disease and preventing metabolic syndrome related to high-fat feeding (Faghihzadeh et al., 2015; Zhao et al., 2019a; Movahed et al., 2020). This evidence concerns the gene GPT and Hepatic steatosis.